A detailed history of Nuveen Asset Management, LLC transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 392,760 shares of RARE stock, worth $16.9 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
392,760
Previous 204,223 92.32%
Holding current value
$16.9 Million
Previous $8.39 Million 159.94%
% of portfolio
0.01%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$40.21 - $59.36 $7.58 Million - $11.2 Million
188,537 Added 92.32%
392,760 $21.8 Million
Q2 2024

Aug 09, 2024

SELL
$37.42 - $51.61 $5.96 Million - $8.21 Million
-159,144 Reduced 43.8%
204,223 $8.39 Million
Q1 2024

May 13, 2024

SELL
$43.02 - $53.69 $4.05 Million - $5.05 Million
-94,080 Reduced 20.57%
363,367 $17 Million
Q4 2023

Feb 14, 2024

BUY
$31.73 - $49.19 $849,570 - $1.32 Million
26,775 Added 6.22%
457,447 $21.9 Million
Q3 2023

Nov 14, 2023

SELL
$34.92 - $46.66 $35,548 - $47,499
-1,018 Reduced 0.24%
430,672 $15.4 Million
Q2 2023

Aug 14, 2023

SELL
$37.35 - $52.15 $736,840 - $1.03 Million
-19,728 Reduced 4.37%
431,690 $19.9 Million
Q1 2023

May 15, 2023

SELL
$36.99 - $48.71 $479,057 - $630,843
-12,951 Reduced 2.79%
451,418 $18.1 Million
Q4 2022

Feb 14, 2023

BUY
$33.72 - $46.33 $8.77 Million - $12.1 Million
260,212 Added 127.46%
464,369 $21.5 Million
Q3 2022

Nov 14, 2022

BUY
$39.96 - $66.14 $154,805 - $256,226
3,874 Added 1.93%
204,157 $8.45 Million
Q2 2022

Aug 15, 2022

SELL
$45.8 - $85.4 $2.65 Million - $4.94 Million
-57,862 Reduced 22.41%
200,283 $11.9 Million
Q1 2022

May 16, 2022

BUY
$62.2 - $84.4 $105,118 - $142,636
1,690 Added 0.66%
258,145 $17.8 Million
Q4 2021

Feb 14, 2022

SELL
$73.71 - $87.86 $3.25 Million - $3.87 Million
-44,070 Reduced 14.66%
256,455 $21.6 Million
Q3 2021

Nov 12, 2021

BUY
$77.92 - $102.4 $1.06 Million - $1.39 Million
13,568 Added 4.73%
300,525 $27.1 Million
Q2 2021

Aug 16, 2021

SELL
$92.19 - $115.71 $7.62 Million - $9.57 Million
-82,675 Reduced 22.37%
286,957 $27.4 Million
Q1 2021

May 17, 2021

SELL
$106.9 - $167.73 $3.08 Million - $4.83 Million
-28,791 Reduced 7.23%
369,632 $42.1 Million
Q4 2020

May 17, 2021

SELL
$84.4 - $177.39 $1.31 Million - $2.76 Million
-15,568 Reduced 3.76%
398,423 $55.2 Million
Q4 2020

Feb 16, 2021

BUY
$84.4 - $177.39 $2.5 Million - $5.25 Million
29,585 Added 7.7%
413,991 $57.3 Million
Q3 2020

Nov 16, 2020

SELL
$72.98 - $90.0 $3.66 Million - $4.51 Million
-50,157 Reduced 11.54%
384,406 $31.6 Million
Q2 2020

Aug 14, 2020

BUY
$46.91 - $78.22 $4.85 Million - $8.09 Million
103,472 Added 31.25%
434,563 $34 Million
Q1 2020

May 14, 2020

BUY
$33.8 - $62.9 $957,283 - $1.78 Million
28,322 Added 9.35%
331,091 $14.7 Million
Q4 2019

Feb 14, 2020

BUY
$36.08 - $45.83 $1.06 Million - $1.35 Million
29,383 Added 10.75%
302,769 $12.9 Million
Q3 2019

Nov 14, 2019

SELL
$42.5 - $63.11 $72,037 - $106,971
-1,695 Reduced 0.62%
273,386 $11.7 Million
Q2 2019

Aug 15, 2019

BUY
$54.93 - $74.36 $14.9 Million - $20.1 Million
270,742 Added 6239.73%
275,081 $17.5 Million
Q1 2019

May 14, 2019

BUY
$39.87 - $69.36 $172,995 - $300,953
4,339 New
4,339 $301,000

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.01B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.